Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.
Editorial: new avenues of research on multiple sclerosis from the perspective of chronic cerebrospinal venous insufficiency paradigm.
Acute transverse myelitis: an unusual complication of typhoid fever.
[Application of laser therapy in the physiotherapy of patients with multiple sclerosis].
Teaching NeuroImages: MRI time lag with acute disseminated encephalomyelitis.
[Possibilities of using the 2010 McDonald criteria for early diagnosis of multiple sclerosis.]
Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.
Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
Personality traits of patients with multiple sclerosis and their relationship with clinical characteristics.
The role of microglial activation in disease progression.
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit.
Rhythmic auditory cueing to improve walking in patients with neurological conditions other than Parkinson's disease - what is the evidence?
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.
Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice.
Effective combination of minocycline and interferon-beta in a model of multiple sclerosis.
Lipid microarrays identify key mediators of autoimmune brain inflammation.
Extracting quantitative measures from EAP: a small clinical study using BFOR.
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Enhanced In Vivo Efficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis.
Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in Rats.
Tysabri (natalizumab)
Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D.

Pages